Skip to main content

Rybrevant Disease Interactions

There are 3 disease interactions with Rybrevant (amivantamab).

Moderate

Amivantamab (applies to Rybrevant) ILD/pneumonitis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

Amivantamab can cause interstitial lung disease (ILD)/pneumonitis. Care should be exercised when using this drug in patients with preexisting pulmonary impairment. Amivantamab should be immediately withheld in patients with suspected ILD/pneumonitis and permanently discontinued if ILD/pneumonitis is confirmed. Patients should be monitored for new/worsening symptoms indicative of ILD/pneumonitis.

References

  1. (2021) "Product Information. Rybrevant (amivantamab)." Janssen Biotech, Inc.
Moderate

Amivantamab (applies to Rybrevant) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Care should be exercised when using amivantamab in patients with moderate (total bilirubin 1.5 to 3 times the upper limit of normal [1.5 to 3 x ULN]) to severe (total bilirubin greater than 3 x ULN) liver dysfunction as the pharmacokinetics of amivantamab have not been studied in these patients. No clinically significant differences in the pharmacokinetics of amivantamab were observed based on mild liver dysfunction (total bilirubin up to ULN and AST greater than ULN or total bilirubin greater than ULN and up to 1.5 x ULN).

References

  1. (2021) "Product Information. Rybrevant (amivantamab)." Janssen Biotech, Inc.
Moderate

Amivantamab (applies to Rybrevant) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Care should be exercised when using amivantamab in patients with severe renal dysfunction (CrCl 15 to 29 mL/min) or end-stage renal disease (CrCl less than 15 mL/min) as the pharmacokinetics of amivantamab have not been studied in these patients. No clinically significant differences in the pharmacokinetics of amivantamab were observed based on CrCl 29 to 276 mL/min.

References

  1. (2021) "Product Information. Rybrevant (amivantamab)." Janssen Biotech, Inc.

Rybrevant drug interactions

There are 3 drug interactions with Rybrevant (amivantamab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer